Last Price
8.52
Today's Change
+0.82 (10.64%)
Day's Change
7.88 - 8.81
Trading Volume
3,667,623
Market Cap
2 Billion
Shares Outstanding
315 Million
Avg Volume
1,559,134
Avg Price (50 Days)
6.58
Avg Price (200 Days)
4.07
PE Ratio
-53.22
EPS
-0.16
Earnings Announcement
22-Nov-2024
Previous Close
7.70
Open
7.89
Day's Range
7.88 - 8.81
Year Range
0.975 - 8.81
Trading Volume
3,698,669
1 Day Change
10.58%
5 Day Change
13.53%
1 Month Change
38.91%
3 Month Change
75.57%
6 Month Change
184.78%
Ytd Change
303.55%
1 Year Change
603.72%
3 Year Change
535.45%
5 Year Change
467.67%
10 Year Change
467.67%
Max Change
467.67%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.